Reduced Plasma Cardiac Myosin-Binding Protein-C Concentrations in Cats with Hypertrophic Cardiomyopathy: Evidence from Chronic, Treated Disease.
4 affiliations
- 1Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai 50100, Thailand.
- 2Cardiopulmonary Clinic, Northern Regional Veterinary Healthcare and Learning Center, Faculty of Veterinary Medicine, Chiang Mai University, Chiang Mai 50100, Thailand.
- 3Biomedical Engineering Institute (BMEI), Chiang Mai University, Chiang Mai 50100, Thailand.
- 4Biomedical Engineering and Innovation Research Center, Chiang Mai University, Chiang Mai 50100, Thailand.
Abstract
Hypertrophic cardiomyopathy (HCM), the most common cardiac disease in cats, is associated with genetic variants, including MYBPC3, which encodes cardiac myosin-binding protein C (cMyBP-C), a key sarcomeric protein involved in myocardial contractility. Although circulating cMyBP-C has emerged as a biomarker of myocardial injury in humans, its clinical relevance in feline HCM remains unclear. This study characterized plasma cMyBP-C and N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations across different stages of feline HCM, evaluated their diagnostic performance, and assessed their associations with echocardiographic parameters. A cross-sectional study included 65 cats: 25 healthy cats, 25 with subclinical HCM, and 15 with clinical HCM (chronic and treated). Plasma NT-proBNP was significantly higher in clinical HCM than in healthy cats (p = 0.0117), whereas plasma cMyBP-C was lower in clinical HCM than in subclinical HCM (p = 0.0462) and healthy cats (p = 0.001). At a cut-off of <1.270 ng/mL, plasma cMyBP-C showed 76.19% sensitivity and 65.38% specificity for distinguishing HCM. NT-proBNP alone showed higher overall diagnostic accuracy (76.67%) than the combined use of cMyBP-C and NT-proBNP. Neither plasma NT-proBNP nor cMyBP-C correlated significantly with echocardiographic parameters. Reduced circulating cMyBP-C concentrations in cats with chronic, treated HCM suggest a biomarker pattern distinct from that reported in acute myocardial injury and warrant further investigation.
Related
- Research trends and hotspot analysis of sudden cardiac death in hypertrophic cardiomyopathy : A bibliometric analysis
- Artificial Intelligence-Enhanced Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy: Diagnosis, Phenotypic Characterization, and Risk Prediction
- Left Ventricular Wall Thickness in Hypertrophic Cardiomyopathy and Cardiac Amyloidosis: A Multimodality Imaging Comparison
- The cardiac myosin binding protein-C–myosin S2 interaction: modulation of cardiac contractility and its role in hypertrophic cardiomyopathy☆
- Clinical effectiveness of mavacamten on cardiac function and disease-related indicators in patients with obstructive hypertrophic cardiomyopathy
BibTeX
@article{tanakwang2026reduced,
title = {{Reduced Plasma Cardiac Myosin-Binding Protein-C Concentrations in Cats with Hypertrophic Cardiomyopathy: Evidence from Chronic, Treated Disease.}},
author = {Nutcha Tanakwang and Natcha Sakunasing and Sarawut Kumphune and Raktham Mektrirat and Kannika Na Lampang and Chavalit Boonyapakorn and Wanpitak Pongkan},
journal = {Animals : an open access journal from MDPI},
year = {2026},
month = sep,
doi = {10.3390/ani16193084},
url = {https://europepmc.org/article/MED/42883053},
note = {CC BY},
}
RIS
TY - JOUR
TI - Reduced Plasma Cardiac Myosin-Binding Protein-C Concentrations in Cats with Hypertrophic Cardiomyopathy: Evidence from Chronic, Treated Disease.
AU - Nutcha Tanakwang
AU - Natcha Sakunasing
AU - Sarawut Kumphune
AU - Raktham Mektrirat
AU - Kannika Na Lampang
AU - Chavalit Boonyapakorn
AU - Wanpitak Pongkan
PY - 2026
DA - 2026/09/30
JO - Animals : an open access journal from MDPI
DO - 10.3390/ani16193084
UR - https://europepmc.org/article/MED/42883053
AB - Hypertrophic cardiomyopathy (HCM), the most common cardiac disease in cats, is associated with genetic variants, including MYBPC3, which encodes cardiac myosin-binding protein C (cMyBP-C), a key sarcomeric protein involved in myocardial contractility. Although circulating cMyBP-C has emerged as a biomarker of myocardial injury in humans, its clinical relevance in feline HCM remains unclear. This study characterized plasma cMyBP-C and N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations across different stages of feline HCM, evaluated their diagnostic performance, and assessed their associations with echocardiographic parameters. A cross-sectional study included 65 cats: 25 healthy cats, 25 with subclinical HCM, and 15 with clinical HCM (chronic and treated). Plasma NT-proBNP was significantly higher in clinical HCM than in healthy cats (p = 0.0117), whereas plasma cMyBP-C was lower in clinical HCM than in subclinical HCM (p = 0.0462) and healthy cats (p = 0.001). At a cut-off of <1.270 ng/mL, plasma cMyBP-C showed 76.19% sensitivity and 65.38% specificity for distinguishing HCM. NT-proBNP alone showed higher overall diagnostic accuracy (76.67%) than the combined use of cMyBP-C and NT-proBNP. Neither plasma NT-proBNP nor cMyBP-C correlated significantly with echocardiographic parameters. Reduced circulating cMyBP-C concentrations in cats with chronic, treated HCM suggest a biomarker pattern distinct from that reported in acute myocardial injury and warrant further investigation.
SN - 2076-2615
ER -